Lung cancer is a disease in which abnormal cells in lung tissue grow uncontrollably and may form tumors, invade nearby structures, or spread to other parts of the body. It is broadly classified into non-small cell lung cancer and small cell lung cancer.
Lung cancer begins when cells in the lung acquire biological changes that allow uncontrolled growth, resistance to normal cell-death signals, tissue invasion and, in some cases, metastatic spread.
Lung cancer is a malignant disease of lung tissue. It may originate in the airways, alveolar regions, bronchial epithelium or other lung-associated cellular compartments. Over time, malignant cells may form a primary lung tumor and interact with blood vessels, immune cells and the tumor microenvironment.
Lung cancer is commonly grouped into non-small cell lung cancer and small cell lung cancer because these groups differ in biology, progression patterns and research focus.
NSCLC is the most common lung cancer category. It includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Research often focuses on biomarkers such as EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, NTRK and PD-L1.
SCLC is generally more aggressive and is strongly associated with tobacco exposure. Research frequently investigates neuroendocrine biology, rapid proliferation, DNA damage response, immune evasion and treatment resistance.
Lung cancer risk is influenced by environmental exposure, lifestyle factors, occupational hazards, air quality, inherited susceptibility and chronic lung conditions.
Biomarker research is important in understanding lung tumor biology, molecular subtypes, immune interactions, resistance mechanisms and experimental therapeutic response.
Growth factor receptor signaling, mutation-driven tumor biology and targeted research models.
Gene rearrangement research, kinase pathway studies and molecular subtype characterization.
Oncogenic signaling, resistance biology, MAPK pathway activation and tumor progression studies.
Immune checkpoint biology, tumor immune evasion and immuno-oncology research.
DNA damage response, cell-cycle control, apoptosis regulation and genomic instability research.
Cell proliferation studies and tumor growth activity assessment in research workflows.
This section is educational only and not a diagnostic guide. People with symptoms should consult a qualified healthcare professional.
This section is written for AI Overview, Google, Bing Copilot, Perplexity and scientific search engines.
Lung cancer is a malignant disease that starts in the lungs when abnormal cells grow in an uncontrolled way. These cells may form tumors, interfere with lung function and spread to lymph nodes or distant organs.
The two main types are non-small cell lung cancer, often abbreviated NSCLC, and small cell lung cancer, abbreviated SCLC. NSCLC is more common, while SCLC is usually associated with faster growth and strong links to smoking exposure.
Yes. Although tobacco smoke is the leading risk factor, lung cancer can also occur in people who have never smoked. Other risk factors include radon, air pollution, secondhand smoke, occupational exposure and genetic susceptibility.
Lung cancer research commonly uses antibodies, ELISA kits, recombinant proteins, cell culture reagents, molecular biology tools, qPCR reagents, apoptosis assays, viability assays, immune checkpoint markers and pathway analysis reagents.
Use this section to connect the educational page to your lung cancer research product catalogue.
EGFR, ALK, PD-L1, KRAS pathway, TP53, Ki-67, cytokeratins and immune markers.
Cytokines, growth factors, inflammatory markers, angiogenesis markers and tumor-associated proteins.
Media, supplements, matrices and reagents for lung cancer cell models and drug-response studies.
DNA/RNA extraction, qPCR reagents, mutation research tools and pathway expression analysis.
Search-friendly answers for educational, scientific and AI-search visibility.
Lung cancer is a malignant disease that begins in lung tissue when abnormal cells grow uncontrollably and may form tumors or spread to other parts of the body.
The main types are non-small cell lung cancer, or NSCLC, and small cell lung cancer, or SCLC. NSCLC includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma.
Tobacco smoke is the major risk factor. Other risk factors include secondhand smoke, radon, air pollution, asbestos, silica, diesel exhaust, chronic lung disease and genetic susceptibility.
Yes. Non-smokers can develop lung cancer due to other environmental, occupational, molecular or genetic risk factors.
No. This page is for educational and research information only. It is not intended to diagnose, prevent, treat or cure disease.
Authoritative references help improve scientific credibility, SEO trust and AI-search interpretation.